Lineage Cell Therapeutics
LCTX
114 hedge funds and large institutions have $85.6M invested in Lineage Cell Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 7 closing their positions.
5,700% more call options, than puts
Call options by funds: $58K | Put options by funds: $1K
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
1% more funds holding
Funds holding: 113 → 114 (+1)
0.07% more ownership
Funds ownership: 50.01% → 50.08% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less capital invested
Capital invested by funds: $94.2M → $85.6M (-$8.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$334K |
| 2 |
Morgan Stanley
New York
|
+$298K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$278K |
| 4 |
Barclays
London,
United Kingdom
|
+$148K |
| 5 |
RA
Raffles Associates
New York
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$580K |
| 2 |
Renaissance Technologies
New York
|
-$358K |
| 3 |
PGP
Prescott General Partners
Boca Raton,
Florida
|
-$217K |
| 4 |
Millennium Management
New York
|
-$169K |
| 5 |
Jane Street
New York
|
-$114K |
LCTX Hedge Fund Activity: Q3 2024 in Review
114 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2024, worth a combined $85.6M — down 9.1% from $94.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LCTX positions and 7 closed out — a net gain of 1 holder — while 30 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $334K. The largest seller was Royal Bank of Canada, cutting an estimated $580K.
- 114 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2024, up from 113 in Q2 2024.
- Funds reported $85.6M of Lineage Cell Therapeutics stock for Q3 2024, down 9.1% quarter-over-quarter.
- 8 funds opened new Lineage Cell Therapeutics positions in Q3 2024 and 7 closed out, a net change of +1 holder.
- The largest Lineage Cell Therapeutics buyer in Q3 2024 was BlackRock, an estimated $334K added.
- The largest Lineage Cell Therapeutics seller in Q3 2024 was Royal Bank of Canada, an estimated $580K sold.
Based on aggregated 13F filings for Q3 2024.